Tarik Soliman, Cambridge, MA (US); Laura M. Hales, Cambridge, MA (US); Daniel B. Hall, Easton, MA (US); Christopher So, Henderson, NV (US); Howard P. Sard, Arlington, MA (US); and Vishnumurthy Hegde, Chelmsford, MA (US)
Assigned to Extend Biosciences, Inc., Newton, MA (US)
Filed by Extend Biosciences, Inc., Newton, MA (US)
Filed on Jul. 3, 2020, as Appl. No. 16/920,652.
Application 16/920,652 is a division of application No. 15/430,449, filed on Feb. 11, 2017, granted, now 10,702,574.
Application 15/430,449 is a continuation of application No. 14/919,601, filed on Oct. 21, 2015, granted, now 9,585,934.
Claims priority of provisional application 62/244,181, filed on Oct. 20, 2015.
Claims priority of provisional application 62/067,388, filed on Oct. 22, 2014.
Prior Publication US 2021/0008153 A1, Jan. 14, 2021
1. A method of treating osteoporosis or hypoparathyroidism in a patient in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising a carrier-drug conjugate comprising a targeting group that is a vitamin D that is not hydroxylated at the carbon 1 position conjugated via a scaffold to a therapeutic peptide at the carbon 3 position of said vitamin D targeting group, wherein said targeting group interacts with the vitamin D binding protein (DBP) to increase the absorption, bioavailability, or half-life of said therapeutic peptide in circulation when compared to a form of said therapeutic peptide conjugated to said vitamin D targeting group at the carbon 25 position; wherein said therapeutic peptide has PTH activity and comprises an amino acid sequence with at least a 90% sequence identity to either SEQ ID NO:10 or SEO ID NO:17.